Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1007/s11886-019-1198-5

http://scihub22266oqcxt.onion/10.1007/s11886-019-1198-5
suck pdf from google scholar
31471666!6717183!31471666
unlimited free pdf from europmc31471666    free
PDF from PMC    free
html from PMC    free
PDF vom PMID31471666  :  Publisher

suck abstract from ncbi

pmid31471666
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios #MMPMID31471666
  • McClure GR; Kaplovitch E; Narula S; Bhagirath VC; Anand SS
  • Curr Cardiol Rep 2019[Aug]; 21 (10): 115 PMID31471666show ga
  • PURPOSE OF REVIEW: Peripheral artery disease (PAD) affects an estimated 200 million people worldwide and is associated with significant cardiovascular morbidity and mortality. Cardiovascular risk is further increased among individuals with polyvascular disease, where either cerebrovascular or coronary artery disease is present in addition to PAD. In this review, we present common clinical scenarios encountered when managing patients with PAD and provide an evidence-based approach to prescribing optimal antithrombotics in this population. RECENT FINDINGS: The COMPASS trial recently demonstrated that rivaroxaban 2.5 mg BID + ASA daily significantly reduces major adverse cardiac and limb events in patients with PAD. Despite these advances, morbidity following MALE events remains high. With widespread approval by federal health regulators, the COMPASS regimen should be strongly considered in PAD patients who do not have a high bleeding risk. Implementing the COMPASS regimen in patients with PAD, along with other vascular risk reduction strategies, will have a substantial impact on reducing atherothromboembolic risk in patients with established vascular disease.
  • |Anticoagulants/*therapeutic use[MESH]
  • |Aspirin/administration & dosage/*therapeutic use[MESH]
  • |COVID-19/drug therapy[MESH]
  • |Cardiovascular Diseases/*prevention & control[MESH]
  • |Coronavirus Infections/drug therapy[MESH]
  • |Drug Therapy, Combination[MESH]
  • |Factor Xa Inhibitors/administration & dosage/*therapeutic use[MESH]
  • |Fibrinolytic Agents/therapeutic use[MESH]
  • |Humans[MESH]
  • |Peripheral Arterial Disease/*drug therapy[MESH]
  • |Platelet Aggregation Inhibitors/administration & dosage[MESH]
  • |Rivaroxaban/administration & dosage/*therapeutic use[MESH]
  • |Thrombolytic Therapy[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    115 10.21 2019